Patient Baseline Characteristics (n = 1,535)
| Characteristic | 90Y-DOTATOC (n = 1,093) | 177Lu-DOTATOC (n = 141) | 177Lu-DOTATOC plus 90Y-DOTATOC (n = 301) | All patients (n = 1,535) |
| Sex | ||||
| Female | 471 (43.1%) | 59 (41.8%) | 120 (39.9%) | 650 (42.3%) |
| Male | 622 (56.9%) | 82 (58.2%) | 181 (60.1%) | 885 (57.7%) |
| Age (y) | ||||
| Median | 58.9 | 62.4 | 59.0 | 59.2 |
| Range | 11.2–86.5 | 14.8–83.4 | 23.2–82.1 | 11.2–86.5 |
| Disease duration (mo) | ||||
| Median | 22.8 | 16.6 | 18.7 | 21.8 |
| Range | 0.0–460.0 | 1.2–374.7 | 0.8–623.4 | 0.0–623.4 |
| Pretreatment | ||||
| Surgery | 597 (54.6%) | 79 (56.0%) | 194 (64.5%) | 870 (56.7%) |
| Chemotherapy | 344 (31.5%) | 46 (32.6%) | 82 (27.2%) | 472 (30.7%) |
| Radiation | 143 (13.1%) | 17 (12.1%) | 31 (10.3%) | 191 (12.4%) |
| Pancreas surgery | 301 (27.5%) | 25 (17.7%) | 81 (26.9%) | 407 (26.5%) |
| DOTATOC cycles | ||||
| Median | 2 | 2 | 3 | 2 |
| Range | 1–10 | 1–5 | 2–11 | 1–11 |
| Cumulative activity in MBq (mCi) | ||||
| Median | 12,950 (350) | 14,800 (400) | 22,200 (600) | 14,060 (380) |
| Range | 1,665–62,160 (45–1,680) | 7,400–37,000 (200–1,000) | 11,840–60,310 (320–1,630) | 1,665–62,160 (45–1,680) |
| Histology | ||||
| Carcinoids | 482 (44.1%) | 61 (43.3%) | 145 (48.2%) | 688 (44.8%) |
| pNET | 326 (29.9%) | 26 (18.4%) | 88 (29.2%) | 440 (28.7%) |
| Rare NET | 100 (9.1%) | 24 (17.0%) | 26 (8.6%) | 150 (9.8%) |
| Unknown primary | 185 (16.9%) | 30 (21.3%) | 42 (14.0%) | 257 (16.7%) |
| Diabetes mellitus at baseline | 124 (11.3%) | 24 (17.0%) | 38 (12.6%) | 186 (12.1%) |
pNET = pancreatic neuroendocrine tumors.